Brief: Spyre Therapeutics Announces Topline Results From The Rheumatoid Arthritis Sub-Study Of The Skyway Phase 2 Trial Of Spy072
BRIEF-Spyre Therapeutics Announces Topline Results From The Rheumatoid Arthritis Sub-Study Of The Skyway Phase 2 Trial Of Spy072 Aug 25 (Reuters) - Spyre Therapeutics Inc SYRE.O:
SPYRE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE RHEUMATOID ARTHRITIS SUB-STUDY OF THE SKYWAY PHASE 2 TRIAL OF SPY072
SPYRE THERAPEUTICS - SPY072 WELL TOLERATED WITH ADVERSE EVENT RATES COMPARABLE TO PLACEBO
SPYRE THERAPEUTICS - SPY072 SHOWS STATISTICALLY SIGNIFICANT BENEFITS VERSUS PLACEBO ON MULTIPLE ENDPOINTS
SPYRE THERAPEUTICS - TOPLINE DATA FOR SPY072 IN PSA AND AXSPA EXPECTED Q4 2026
SPYRE THERAPEUTICS INC - MAGNITUDE OF EFFECT DID NOT MEET COMPANY'S TARGET TO PRIORITIZE MONOTHERAPY DEVELOPMENT OF SPY072 IN RHEUMATOID ARTHRITIS
SPYRE THERAPEUTICS INC: SPY072 IN COMBINATION WITH IL17-A/F IN HIDRADENITIS SUPPURATIVA (HS) IN LATE 2027 OR EARLY 2028
Source text: ID:nGNX2qPzTf
Further company coverage: SYRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spyre Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
U.S. STOCKS ON THE MOVE-MYR Group, Spyre Therapeutics, AMD
Spyre Therapeutics slips on $350 mln share sale
Brief: Spyre Therapeutics Announces Pricing Of $350.0 Million Public Offering Of Common Stock